MiR-106a Associated with Diabetic Peripheral Neuropathy Through the Regulation of 12/15-LOX-meidiated Oxidative/Nitrative Stress

Curr Neurovasc Res. 2017;14(2):117-124. doi: 10.2174/1567202614666170404115912.

Abstract

Background: Diabetic peripheral neuropathy (DPN) is a common complication of diabetes with a complex pathogenesis. Study has reported that oxidative stress and nitrative stress are all involved in the DPN. However, the mechanism between them is still unclear. In the present study, we investigated whether miR-106a regulated 12/15-Lipoxygenase (12/15-LOX) of oxidative/nitrative stress (OS/NS) in DPN.

Methods: Dorsal root ganglion (DRG) was isolated from 10 healthy mice and 10 DPN mice. DPN mouse model was established by the injection of streptozotocin (STZ), and high glucose was used for inducing the in vitro model of DPN.

Results: In DPN mice, the levels of fasting blood-glucose (FBG) level, Methane Dicarboxylic Aldehyde (MDA) and the Inducible Nitric Oxide Synthase (iNOS) were increased, while the levels of motor nerve conduction velocity (MNCV), sensory nerve conduction velocity (SNCV) and superoxide dismutase (SOD) were decreased. MiR-106a level in DRG cells of DPN was decreased. The 12/15-LOX expression and cell apoptosis were increased. DRG cells subjected to high glucose resulted in the same effects as above. MiR-106a was observed to target 12/15-LOX and regulated its expression. MiR-106a overexpression reversed the effect that was induced by high glucose, however, overexpression of 12/15-LOX reversed the effect that was induced by miR-106a overexpression.

Conclusion: MiR-106 may be associated with 12/15-LOX mediated OS/NS in DPN and may be considered as a potential therapeutic target.

Keywords: 12/15-LOX; Diabetic peripheral neuropathy; diabetic mellitus; micro-106a; nitrative stress; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / toxicity
  • Arachidonate 12-Lipoxygenase / metabolism*
  • Arachidonate 15-Lipoxygenase / metabolism*
  • Blood Glucose / drug effects
  • Diabetic Neuropathies / chemically induced
  • Diabetic Neuropathies / pathology*
  • Disease Models, Animal
  • Fasting / blood
  • Ganglia, Spinal / drug effects
  • Ganglia, Spinal / metabolism*
  • Glucose / pharmacology
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Neural Conduction / drug effects
  • Neurons / drug effects
  • Neurons / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Oxidative Stress / drug effects*
  • Random Allocation
  • Streptozocin / toxicity
  • Superoxide Dismutase / metabolism
  • Thiazolidinediones / metabolism
  • Up-Regulation / drug effects
  • Up-Regulation / genetics
  • Up-Regulation / physiology*

Substances

  • (Z)2-(5-(4-methoxybenzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid
  • 12-15-lipoxygenase
  • Antibiotics, Antineoplastic
  • Blood Glucose
  • MicroRNAs
  • Mirn106 microRNA, mouse
  • Thiazolidinediones
  • Streptozocin
  • Arachidonate 12-Lipoxygenase
  • Arachidonate 15-Lipoxygenase
  • Nitric Oxide Synthase Type II
  • Superoxide Dismutase
  • Glucose